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Abstract
Introduction Delivery of crushed ticagrelor via a naso-
gastric tube is a widely spread off-label use in unconscious
patients following out-of-hospital cardiac arrest (OHCA).
Notwithstanding the importance of a potent dual anti-
platelet therapy in these patients, the efficacy of crushed
ticagrelor after OHCA has not been established yet.
Methods In a prospective, single-center, observational
trial, 38 consecutive MI patients after OHCA were inclu-
ded. 27 patients (71.1 %) underwent mild induced
hypothermia. The primary outcome was platelet inhibition
at 24h measured by impedance aggregometry.
Results There was sufficient platelet inhibition in most
patients after OHCA. In all hypothermic patients, there was
an adequate platelet inhibition by ticagrelor at 24 h
(p\ 0.001). 15 patients (39.5 %) had significant gastroe-
sophageal reflux and one patient with significant reflux had
inadequate platelet inhibition at 24 h. There were no stent
thrombosis or recurrent atherothrombotic events in these
patients.
Conclusion Administration of crushed ticagrelor via a
nasogastric tube reliably inhibited platelet function in vitro
and in vivo regardless of the presence of hypothermia in
MI patients. Thus, platelet inhibition can be reliably
achieved in MI patients during neuroprotective hypother-
mia following OHCA.
Keywords Neuroprotective hypothermia  Out-of-
hospital cardiac arrest  Ticagrelor  P2Y12 antagonists 
Myocardial infarction
Introduction
Cardiac diseases such as acute myocardial infarction (MI)
are the leading cause for out-of-hospital cardiac arrest
(OHCA) [1]. An effective dual antiplatelet therapy is cru-
cial for the successful clinical management of these high-
risk patients. In the PLATelet inhibition and patient out-
comes (PLATO) trial, ticagrelor was associated with sig-
nificant reductions in cardiovascular events, cardiovascular
mortality, and all-cause mortality in patients presenting
with acute coronary syndromes (ACS) compared to clopi-
dogrel [2].
O. J. Mu¨ller and M. Preusch contributed equally.
















1 Department of Internal Medicine III, University Hospital
Heidelberg, Im Neuenheimer Feld 410, 69120 Heidelberg,
Germany
2 DZHK (German Centre for Cardiovascular Research),
Partner Site, Heidelberg/Mannheim, Germany
123
Clin Res Cardiol (2016) 105:332–340
DOI 10.1007/s00392-015-0925-1
The post-cardiac arrest phase is a complex combination
of various processes, including myocardial dysfunction,
systemic ischemia/reperfusion response and brain injury
[3–5]. These effects lead to an activation of endogenous
coagulation and anticoagulation, acidosis, and pro-inflam-
matory mechanisms, which can alter platelet count and
function [6–9]. Systemic hypoxemia also involves the GI
tract, potentially reducing the absorption and metaboliza-
tion of enterally applied drugs. Malabsorption may be even
worsened by the application of sedatives and analgesics
such as opioids. In addition, treatment strategies such as
therapeutic hypothermia can affect platelet function as well
as the response to medication, especially if enzymatic
activation of the drug is required [6, 10, 11]. Acidosis and
pro-inflammatory processes in the post-cardiac arrest phase
can have an impact on blood coagulation and platelet
function [4, 12, 13]. In addition, activation of the coagu-
lation and anticoagulation system as well as simultaneous
activation of endogenous fibrinolysis and anti-fibrinolysis
may contribute to microcirculatory reperfusion disorders
[14, 15]. During the post-cardiac arrest phase with ongoing
hypothermia, platelet inhibition by clopidogrel is almost
nonexistent [16–18]. Unlike clopidogrel, ticagrelor does
not require cytochrome p450 (CYP) conversion and there
are no genetic polymorphisms known that may result in a
loss of function, and therefore be of disadvantage in
patients after OHCA [19].
Cardiac arrest survivors caused by a MI are particularly
in need for a potent antithrombotic medication, and tica-
grelor is commonly used in these patients. However,
application, metabolism, and action conditions of ticagrelor
during the early post-cardiac arrest phase differ substan-
tially from the setting in previous studies that tested tica-
grelor in cardio-circulatory stable MI patients. Therefore,
the aim of this study was to evaluate the efficacy of tica-
grelor in MI patients with and without therapeutic
hypothermia following OHCA.
Methods
The study was approved by the Ethics Committee of Hei-
delberg (approval reference number S-388/2011) and
complies with the principles laid down in the Declaration
of Helsinki. Informed consent was obtained from the legal
guardians or the next kin. Surviving patients, who regained
a good mental state, confirmed the consent to participate in
the study later on.
Design
We conducted a prospective, single-center, observational
study. Patients after OHCA and suspected ACS were
admitted to the intensive care unit of the Department of
Cardiology of the University Hospital of Heidelberg and
added to the database of the Heidelberg Resuscitation
Registry. Prior to admission, patients were treated with
unfractioned intravenous heparin and intravenous ASA. If
the suspected diagnosis was ACS (e.g., by anamnesis or
changes in the electrocardiogram), patients were loaded
with ticagrelor. The loading dose was 180 mg followed by
90 mg twice a day. Ticagrelor tablets were crushed, sus-
pended in 10–20 mL aqua, and administered with a stan-
dard 20 mL polyethylene/polypropylene oral dispenser
syringe (Exadoral, B. Braun Melsungen AG, Melsungen,
Germany) via a standard 15 French polyurethane naso-
gastric tube (Freka Tube, Fresenius Kabi AG, Bad
Homburg, Germany) followed by 10 mL of flush with
aqua. If possible ticagrelor was administered directly after
admission. Patients underwent a cardiac catheterization and
intensive care treatment according to the standards of the
intensive care unit. Patients underwent mild therapeutic
hypothermia unless bystanders witnessed the cardiac arrest
and initiated an adequate basic life support immediately.
Also, MI patients with contraindications against
hypothermia (e.g., highly elevated bleeding risk) and
patients who showed early signs of awakening shortly after
return of spontaneous circulation (ROSC) were included
into the control group. In all other patients after OHCA,
therapeutic hypothermia was induced by cold saline infu-
sion and sustained via intravasal catheter cooling. Because
of this selection bias, the study is not designed to compare
clinical outcomes between hypothermic and non-hy-
pothermic patients. After reaching the target temperature of
33 ± 1 C, hypothermia was continued for 24 h followed
by controlled rewarming at max. 0.5 C/h using a standard
intravenous cooling catheter (IcyCath, ZOLL, Sunnyvale,
CA, USA). Core temperature was measured by a urine
thermo-catheter. Sedatives and analgesics (midazolam and
sufentanil) were used during hypothermia to suppress
shivering.
Survival, neurological outcome in terms of the cerebral
performance category scale, and major adverse cardiac
events including stent thrombosis were followed at least
until hospital discharge. Bleeding events were defined by
the BARC bleeding definition. All patients received a close
monitoring of important laboratory tests including high-
sensitivity troponin T [20]. Patients were followed until
discharge of the hospital.
To further elucidate the effects of body temperature on
platelet aggregometry, a second cohort of stable patients on
dual platelet inhibition was investigated. Only cardio-cir-
culatory stable patients with a regular oral intake of either
ticagrelor or clopidogrel were included in this substudy. MI
patients received ticagrelor (loading dose 180 mg followed
by 90 mg twice a day), whereas patients with a
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stable coronary disease received clopidogrel (loading dose
300–600 mg followed by 75 mg once a day). Platelet
function monitoring was performed by impedance aggre-
gometry[24 h after loading.
Inclusion and exclusion criteria
Survivors of out-of-hospital cardiac arrest due to a MI
(NSTEMI and STEMI) were eligible for the study. Only
patients who survived [24 h after admission were
included into the study. Exclusion criteria were mainly
uncontrolled bleeding or other contraindication for the
delivery of ticagrelor. Also, patients with prior intake of
a P2Y12 antagonist were excluded. Furthermore, oral
anticoagulation with a vitamin K antagonist (INR within
the therapeutic range) or intake of a direct oral antico-
agulant were exclusion criteria. The peri-interventional
use of a glycoprotein IIb/IIIa inhibitor (eptifibatide, tir-
ofiban) did not lead to an exclusion of the patient as long
as platelet function measurements were more than 8 h
apart from the end of the glycoprotein IIb/IIIa inhibitor
therapy [21].
Platelet impedance aggregometry
Platelet function monitoring was performed by impedance
aggregometry 24 h after admission, when all patients had
received at least two doses of ticagrelor. All patients in the
hypothermia group were still at 33 C at the time point of
measurements. Electrical aggregometry measures the
impedance between a pair of electrodes immersed in
diluted whole blood. The increase in impedance (X) is
associated with the amount of platelet aggregates deposited
on the electrodes after the addition of a platelet agonist
[22]. Details of the aggregometry method have been
reported before [23, 24]. Aggregation was analyzed by the
use of a CA560-CA lumi-aggregometer from Chrono-Log.
Aggregometry was performed at 37 C with a constant stir
bar speed of 1000 rpm. In brief, a 0.5 mL aliquot of citrate-
anticoagulated whole blood was diluted with 1 volume of
prewarmed (37 C) NaCl (9 g/L) in a polycarbonate cuv-
ette. The electrodes were then immersed in the diluted
blood sample and incubated at 37 C for at least 2 min.
After electrical calibration, aggregation was started by the
addition of ADP to obtain a final concentration of 5 or
20 lmol/L. The increase of impedance (X) was recorded
for 7 min. Only 6-min impedance values were used for the
analyses. ADP (1 mmol/L; Chrono-Par reagent no.
070212), cuvettes, and siliconized stir bars were purchased
from Probe&Go GmbH (Osburg, Germany). An increase in
impedance of\6 X was considered as good responsiveness
to ticagrelor. An increase of C6 X was classified as
insufficient platelet inhibition with ticagrelor.
Statistical analysis
Data are presented as mean ± standard deviation (SD). A
p value \0.05 was considered statistically significant
(IBM SPSS Statistics, Version 21.0.0). A one-sided
binomial test (G*Power 3.1, Institute for Experimental
Physics, University of Du¨sseldorf, Germany) was used to
determine a sample size of n = 23 hypothermic patients
for a given power (1 - b) = 0.9 and a = 0.05, assuming
that enteral delivery of ticagrelor results in insufficient
platelet inhibition in less or equal to 30 % of hypothermic
patients (effect size = 0.3). For post hoc validation, we
calculated a two-sided binomial test (r statistics 3.0.2). A
paired t test was used to compare differences in impedance
between hypothermic and normothermic samples (IBM
SPSS Statistics, Version 21.0.0).
Results
General and cardiac outcomes
A total of consecutive 38 patients with STEMI or NSTEMI
after OHCA were included into the analysis (30 male and 8
female patients; ages 42 to 91 years; Table 1). Of these
primary OHCA survivors, about a third died despite max-
imum intensive care treatment (intrahospital mortality
36.8 %). 24 patients could be discharged from hospital.
Using the Utstein reporting guidelines for the cerebral
performance category (CPC) for neurologic outcome [25],
17 patients (44.7 %) were classified as CPC 1 or CPC 2.
There were no cases of stent thrombosis, recurrent MI,
or unscheduled re-angiography within the hospital stay.
Most deaths were attributed to fatal hypoxic brain damage,
while other patients died despite maximum intensive care
treatment in a catecholamine refractory cardiogenic shock.
Of note, in none of the 27 patients, hypothermia had to be
discontinued ahead of schedule.
On admission, all but three patients had elevated white
blood cell counts. C-reactive protein levels were within the
normal range or mildly elevated in most patients on
admission, but started to increase within 24 h (Table 2).
Platelet aggregation
Platelet function was measured by impedance aggregom-
etry 25.6 ± 13.6 h after OHCA. 37 out of 38 (97.4 %)
patients had a sufficient platelet inhibition within 24 h after
admission. In the hypothermia group, impedance aggre-
gometry showed a good efficacy of ticagrelor in all patients
(Fig. 1a). In the non-hypothermic group, one patient with
significant gastroesophageal reflux had insufficient platelet
inhibition by ticagrelor 24 h after admission. Platelet
334 Clin Res Cardiol (2016) 105:332–340
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function was measured after re-application of a loading
dose of ticagrelor (180 mg) and showed sufficient inhibi-
tion in this patient at 48 h. Other than that there were no
hints that gastroesophageal reflux significantly affects
platelet inhibition by ticagrelor (Fig. 1b). There was no
significant correlation between the impedance measured by
platelet aggregometry and neither the core body tempera-
ture on admission nor the body temperature at the time
point of loading with ticagrelor (Fig. 2a ? b). Further-
more, there neither was an association between impedance
and hs-CRP as a marker for inflammation nor between
impedance and pH as a surrogate parameter for acidosis
(Fig. 2c ? d).
To assess how the temperature of the instruments and
blood samples affect the aggregometry results, we com-
pared the platelet aggregation at 33 and at 37 C in a
Table 1 Patient demographics
Hypothermia (n = 27) No hypothermia (n = 11)
Age (years) 61.4 ± 10.5 64.6 ± 10.9
STEMI vs. NSTEMI (n) 11 (40.7 %) vs. 16 (59.3 %) 5 (45.5 %) vs. 6 (54.4 %)
LVF
Normal to mildly impaired (n) 3 (11.1 %) 2 (18.2 %)
Moderately impaired (n) 9 (33.3 %) 3 (27.3 %)
Highly impaired (n) 15 (55.5 %) 6 (54.5 %)
3 vessel CAD (n) 18 (66.7 %) 7 (63.6 %)
Time to ROSC (min) 24.7 ± 12.4 18.6 ± 12.2
Discharge from hospital (n) 16 (59.3 %) 8 (72.7 %)
Neurologic outcome
CPC 1 and CPC 2 (n) 10 (37.0 %) 7 (63.6 %)
CPC 3 and CPC 4 (n) 6 (22.2 %) 1 (9.1 %)
Gastroesophageal reflux (mL) 79.6 ± 127.3 203.0 ± 314.8
Lysis or GPIIa/IIIb inhibitor treatment
Tenecteplase (n; time to measurement) 3 (11.1 %); 30.8 ± 3.9 h 2 (18.2 %); 31 ± 1.1 h
Eptifibatide (n; time to measurement) 2 (7.4 %); 30.5 ± 2.1 h 0 (0 %); n/a
Tirofiban (n; time to measurement) 3 (11.1 %); 21.7 ± 1.5 h 1 (9.1 %); 34 h
Dialysis 0 1 (9.1 %)
Temp. on admission (C) 35.0 ± 1.0 35.6 ± 1.4
Temp. at loading with ticagrelor (C) 34.5 ± 1.1 36.0 ± 1.4
CAD coronary artery disease, CPC cerebral performance category, Dialysis dialysis for acute or chronic
kidney failure, LVF left ventricular function, ROSC return of spontaneous circulation, STEMI ST-elevation
myocardial infraction, Temp. temperature
Table 2 Serum chemistry, blood count and blood gas analysis on admission and at the time point of platelet function measurements









CRP (mg/L) \5 mg/L 9.23 ± 15.24 19.53 ± 15.6 98.64 ± 79.96 101.96 ± 16.61
WBC (nL-1) 4 to 10/nL 17.30 ± 6.91 18.94 ± 6.92 12.54 ± 5.65 16.77 ± 6.92
RBC (g/dL) 12 to 15 g/dL 14.07 ± 1.90 12.50 ± 2.65 12.55 ± 2.02 11.21 ± 1.18
TC (nL-1) 150 to 440/nL 249.0 ± 55.2 318.3 ± 130.4 212.0 ± 60.0 334.6 ± 159.5
pH 7.37 to 7.45 7.21 ± 0.17 7.18 ± 0.11 7.34 ± 0.10 7.40 ± 0.08
BE (mmol/L) -2 to ?3 mmol/L -9.46 ± 6.35 -6.16 ± 4.58 -10.33 ± 5.51 -3.45 ± 3.33
Lactate (mg/dL) \16 mg/dL 52.91 ± 26.79 85.07 ± 49.49 29.53 ± 29.03 22.26 ± 17.69
Hs-TnT (pg/mL) \50 pg/dL 876.1 ± 1348.2 316.5 ± 371.6 3520.4 ± 8503.9a 2898.9 ± 4063.8a
Data presented as mean ± SD
BE base excess, CRP c-reactive protein, RBC red blood count, TC thrombocytes, hs-TnT high-sensitivity troponin T, WBC white blood count
a Hs-TnT measured at day 3 after admission
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separate cohort of cardio-circulatory stable patients on dual
platelet inhibition (Fig. 3a ? b). There was a strong cor-
relation between the paired samples at 33 and 37 C for
clopidogrel (n = 66; R = 0.875; p\ 0.001) and ticagrelor
(n = 19; R = 0.847; p\ 0.001), respectively. The mean
impedance was significantly higher in the cooled samples
than in the samples at body temperature for clopidogrel
(4.61 ± 5.51 vs. 2.68 ± 4.11 X; p\ 0.001) and for tica-
grelor (3.52 ± 4.81 vs. 1.37 ± 1.81 X; p = 0.013). Eight
normothermic patients (12.1 %) receiving clopidogrel had
sufficient platelet inhibition at 37 C, while cooling of the
sample to 33 C suggested insufficient platelet inhibition.
With regard to ticagrelor, three normothermic patients
(15.8 %) would have been reclassified as poor responders
after cooling the blood samples. A shift toward higher
impedance at lower body temperature was also observed in
hypothermic patients, although the difference did not reach
statistical significance (Fig. 2c).
Bleeding events
A total of four patients (17.4 %) experienced bleeding
complications after admission. One patient in the



























Fig. 1 Efficacy of crushed ticagrelor in MI patients after OHCA in
pre-specified subgroups. a Results of the impedance aggregometry
24 h after admission in n = 27 hypothermic patients at 33.0 C body
temperature and n = 11 normothermic patients. b Results of the
impedance aggregometry 24 h after admission in n = 15 patients with
[50 mL gastroesophageal reflux within the first 6 h after admission
and n = 20 patients with\50 mL reflux
A














) p = n.s.














) p = n.s.














) p = n.s.























impedance measured by platelet
aggregometry and the body
temperature a on admission,
b at the time point of loading
with ticagrelor, c pH and d hs-
CRP, respectively
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bleeding with a drop in hemoglobin of[5 g/dL, counting
as a type 3a bleeding according to the definition of the
Bleeding Academic Research Consortium (BARC) [26,
27]. One patient in the non-hypothermia group started to
bleed at the puncture site after coronary angiography fol-
lowing prior out-of-hospital systemic thrombolysis and had
a drop in hemoglobin of[3 g/dL (BARC type 2 bleeding).
Two patients (one in each group, respectively) experienced
less severe complications at the groin (one aneurysm at the
puncture site and the other a large hematoma; BARC type 2
bleedings). Two out of four patients (50 %) with significant
bleeding complications died during hospital care, but none
of the deaths was attributed to bleeding.
Discussion
In this study, we showed that enteral delivery of crushed
and suspended ticagrelor via a nasogastric tube in MI
patients after OHCA is effective in vitro and in vivo.
Induction of therapeutic hypothermia influenced the results
of impedance aggregometry. However, this did not lead to
a major loss of efficacy. Likewise, gastroesophageal reflux,
acidosis and elevated inflammatory markers did not result
in a significant decrease in aggregation efficacy of tica-
grelor in most post-cardiac arrest patients. However, one
patient with pronounced reflux in the non-hypothermia
group showed inadequate platelet inhibition at 24 h.
Therefore, especially in patients with a large amount of
reflux and enteral delivery of a P2Y12 antagonist, platelet
function measurements should be considered.
To our knowledge this is the largest cohort of MI
patients after OHCA on dual platelet inhibition with tica-
grelor. As an additional strength, the impact of temperature
on platelet aggregometry was evaluated. Furthermore, to
have comparable pathophysiological conditions in the
hypothermia group and the control group, only MI patients
after OHCA, when injury pathways are still active, were
included into the study [4]. In contrast, the control group in
two previous studies investigating platelet inhibition in
hypothermia included either stable MI patients without a
history of cardiopulmonary resuscitation [28] or consisted
of patients without MI and without dual platelet inhibition
[29].
Overall survival after OHCA remains low despite
advances in medical therapy and device technology [30,
31]. Of primary survivors admitted to hospital still more
than half of the patients die during their hospital stay [30,
32, 33]. There were no recurrent atherothrombotic events
like stent thrombosis, re-infarctions or unscheduled re-an-
giographies in none of the groups indicating a good clinical
efficacy of the dual antiplatelet therapy. Overall, there were
no early outcomes that pointed toward a clinical drug
resistance to ticagrelor in hypothermic patients after
OHCA. This study cannot provide long-term clinical end-
points. However, after termination of artificial respiration,
resumption of oral drug intake, and normalization of
inflammation and acidosis, a similar long-term efficacy as
in previous trials can be assumed [2].
We observed an inversely proportional relationship
between the blood temperature and the level of impedance
measured by platelet aggregometry. Blood samples taken
from hypothermic patients exhibited a higher impedance at
their actual temperature of 33 C than after rewarming to a
normal human body temperature of 37 C. Likewise,
impedance in blood samples of normothermic patients
taking ticagrelor increased after cooling the samples to
33 C. The observed increase in impedance in hypothermic
patients may reflect a partial loss of efficacy of ticagrelor at
lower temperatures. In previous trials, this observation was
mostly explained by a decreased bioavailability of tica-
grelor due to an impaired GI tract with reflux, decreased GI
motility and absorption dysfunction [28, 29]. However, the
profound platelet inhibition in rewarmed blood samples of
hypothermic patients suggests a sufficient bioavailability of
ticagrelor also after enteral delivery in the post-cardiac
arrest phase. We observed a shift in impedance in the same































Fig. 3 Influence of the temperature of the instrument and the blood
sample on impedance. Results of the impedance aggregometry in
a n = 65 normothermic, stable patients receiving clopidogrel;
b n = 20 normothermic, stable MI patients receiving ticagrelor; and
c n = 6 hypothermic patients after OHCA receiving ticagrelor
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normothermic patients. Thus, ticagrelor as a reversible
allosteric regulator of the P2Y12 receptor might undergo
changes in its binding characteristics that negatively affect
the drug–receptor interaction in hypothermia and in cooled
blood of normothermic patients. On the other hand, we
observed similar effects on clopidogrel, which is an irre-
versible inhibitor of the P2Y12 receptor. Therefore, phar-
macokinetic alterations in the drug–receptor interaction
cannot fully explain the increase in impedance and
potential loss of efficacy after cooling the blood samples of
these normothermic patients with a regular oral clopidogrel
intake.
It is a major issue of all tests used to assess platelet
function that there is no validation of the different testing
systems in hypothermic patients [34, 35]. Several patients
on ticagrelor treatment would have been reclassified as
poor responders after cooling their blood. However, it is
unknown if the seemingly lower degree of platelet inhibi-
tion in cooled blood translates into a worse clinical out-
come. As we did not observe recurrent atherothrombotic
events, we hypothesize that there might be a shift in
standard values at lower temperatures for impedance
aggregometry.
A recent study by Joffre revealed a high incidence of
stent thrombosis (10.9 %) in patients with induced mild
hypothermia after OHCA, regardless of the type of P2Y12
antagonists [36]. However, only half of the patients were
pretreated with acetylsalicylic acid and heparin and none of
the patients was loaded with a P2Y12 antagonist before PCI
and initiation of hypothermia. Similar results have been
reported in post-cardiac arrest patients receiving clopido-
grel [37]. The question was even raised whether brain
salvage using induced hypothermia should be given pri-
ority to the prevention of stent thrombosis [28, 37].
Importantly, most deaths in this study were attributed to
severe hypoxic brain damage. Therefore, therapeutic
strategies for brain salvage are essential for patient out-
come. Of note, the mean time from primary PCI to
thrombotic event in a study of Penela et al. was 174 h,
while hypothermia is usually maintained for 24 (-48 h)
only [37]—indicating that most thrombotic complications
occur long after rewarming. This may question the
hypothesis that acute and temporary changes in blood
coagulation and platelet function during the early post-
cardiac arrest phase are the main reasons for the incidence
of stent thrombosis. In contrast, we and others observed a
much lower incidence of stent thrombosis, even if
hypothermia had been started before PCI [38, 39]. These
differences might be due to variations in out-of-hospital
medical treatment and other locally driven factors. In this
study, all patients without exception received an out-of-
hospital pre-treatment with a full dose of heparin and ASA.
In addition, patients with a suboptimal coronary flow after
revascularization and a high thrombotic burden received a
short-time treatment with a GPIIa/IIIb inhibitor. Unless
there were bleeding complications, patients also received
low-dose heparin along with their dual antiplatelet therapy
during their stay on the intensive care unit.
Furthermore, the time point and the body temperature at
loading with a P2Y12 antagonist might influence the inci-
dence of stent thrombosis as well. In the ATLANTIC trial,
the rate of stent thrombosis in the group that received a
prehospital loading with ticagrelor was lower than in the
in-hospital group [40]. However, until there will be suffi-
cient data regarding intravenous P2Y12 antagonists, a pre-
hospital loading will not be applicable. On admission, most
patients were already in a mild hypothermia. Even more
important, there was no correlation between the degree of
platelet inhibition and the body temperature at the time
point of loading with ticagrelor. Starting or rather main-
taining hypothermia is possible before loading with tica-
grelor. Therefore, platelet inhibition appears to be no
reason to hastily abandon neuroprotective hypothermia or
to postpone its onset. Nevertheless, further pharmacoki-
netic analyses and clinical trials are necessary to assess if
the results of the in vitro tests de facto reflect a partial loss
of efficacy in cooled blood or if the threshold to separate
between responders and non-responders might need to be
redefined in hypothermic patients.
There are several limitations of this study. Impedance
aggregometry is a well-established method for testing
platelet function and response to platelet inhibitors. How-
ever, it would have been of advantage to confirm our
results with other functional platelet tests. Also, we con-
ducted no serial platelet function tests to assess the mini-
mum time interval between loading with ticagrelor and
achievement of sufficient platelet inhibition.
In conclusion, we demonstrated that enteral delivery of
ticagrelor is effective in vitro and in vivo in MI patients
after OHCA. Based on our data, platelet inhibition is no
reason to withhold induced hypothermia in patients during
the early ROSC phase.
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